Clinical Trial Detail

NCT ID NCT01656642
Title A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications

melanoma

Therapies

Atezolizumab + Cobimetinib + Vemurafenib

Atezolizumab + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST